A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

Trial Details

NCT ID
NCT05304377
Phase
PHASE1
Sponsor
Enliven Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ELVN-001
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • The Bronx, New York, United States|40.84985,-73.86641
  • Portland, Oregon, United States|45.52345,-122.67621
  • Houston, Texas, United States|29.76328,-95.36327
  • Adelaide, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • BCR-ABL1 positive CML in chronic phase, with or without T315I mutation.
  • US: The patient has failed or is intolerant to at least one prior second-generation tyrosine kinase inhibitor (TKI) or asciminib. Rest of World: Th…
  • ECOG performance status of 0 to 2.
  • Adequate hematologic, hepatic and renal function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →